{"schema_version":"secwatch.filing_event.v1","accession":"0001513162-21-000162","form_type":"8-K","ticker":"BMRA","cik":"0000073290","company_name":"BIOMERICA INC","filed_at":"2021-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.469716+00:00","generated_at":"2026-06-28T00:42:02.851735+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022","bullets":["Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.","Operating loss expected between $0.9M and $1.3M; logistics constraints and higher shipping costs hurt margins.","Backlog of unfilled orders exceeds $4.0M entering Q3; cash balance over $7M, partly from prepayments.","InFoods IBS clinical trial data collection complete; topline results expected by end of January 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001513162-21-000162","json":"https://secwatch.observer/filing/0001513162-21-000162.json","markdown":"https://secwatch.observer/filing/0001513162-21-000162.md","text":"https://secwatch.observer/filing/0001513162-21-000162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/73290/000151316221000162/0001513162-21-000162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/73290/000151316221000162/bmra-20211216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T00:42:02.851735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}